Sadly, my cousin in Kazakhstan was born blind in one eye, which inspired me to launch a new venture focused on discovering treatments for eye conditions. My uncle earns only $200 per month and has four children, making expensive surgery impossible for him to afford.
KozAI is building a high-throughput platform that combines machine learning with bioelectrical testing to accelerate the discovery of new antioxidant therapies for eye diseases. By integrating ex vivo and in vivo retinal models with multimodal data collection, KozAI can rapidly evaluate drug candidates, pinpoint mechanisms, and streamline the development of transformative treatments for conditions like AMD, Retinitis Pigmentosa, and beyond.
“Ad astra per aspera.”
— Through hardships to the stars.
